Biovitrum AB entered its first major commercial alliance, a deal potentially worth up to US$150 million with GlaxoSmithKline plc to develop and commercialize its collection of proprietary 5-hydroxytryptamine 2C receptor agonists for the treatment of obesity and other indications. (BioWorld International) Read More
